-
1Academic Journal
المؤلفون: N. E. Kushlinskii, O. V. Kovaleva, E. S. Gershtein, A. A. Alferov, Yu. B. Kuzmin, S. D. Bezhanova, I. A. Klimanov, N. V. Lyubimova, A. N. Gratchev, N. N. Zybina, V. B. Matveev, I. S. Stilidi, Н. Е. Кушлинский, О. В. Ковалева, Е. С. Герштейн, А. А. Алферов, Ю. Б. Кузьмин, С. Д. Бежанова, И. А. Климанов, Н. В. Любимова, А. Н. Грачев, Н. Н. Зыбина, В. Б. Матвеев, И. С. Стилиди
المصدر: Cancer Urology; Том 19, № 4 (2023); 24-31 ; Онкоурология; Том 19, № 4 (2023); 24-31 ; 1996-1812 ; 1726-9776
مصطلحات موضوعية: сыворотка крови, KISS1, blood serum
وصف الملف: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/1724/1492; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1724/1408; Kushlinskii N.E., Gershtein E.S., Alferov A.A. et al. Prognostic role of matrix metalloproteinases 2, 7, 8, 9 and their type 1 tissue inhibitor in blood serum of patients with kidney cancer. Bull Exp Biol Med 2020;168(5):673–6. DOI:10.1007/s10517-020-04778-w; Steeg P.S., Ouatas T., Halverson D. et al. Metastasis suppressor genes: basic biology and potential clinical use. Clin Breast Cancer 2003;4(1):51–62. DOI:10.3816/cbc.2003.n.012; Ly T., Harihar S., Welch D.R. KISS1 in metastatic cancer research and treatment: potential and paradoxes. Cancer Metastasis Rev 2020;39(3):739–54. DOI:10.1007/s10555-020-09868-9; Harihar S., Welch D.R. KISS1 metastasis suppressor in tumor dormancy: a potential therapeutic target for metastatic cancers? Cancer Metastasis Rev 2023;42(1):183–96. DOI:10.1007/s10555-023-10090-6; Hu K.L., Chang H.M., Zhao H.C. et al. Potential roles for the kisspeptin/kisspeptin receptor system in implantation and placentation. Hum Reprod Update 2019;25(3):326–43. DOI:10.1093/humupd/dmy046; Wang C.H., Qiao C., Wang R.C., Zhou W.P. KiSS-1-mediated suppression of the invasive ability of human pancreatic carcinoma cells is not dependent on the level of KiSS-1 receptor GPR54. Mol Med Rep 2016;13(1):123–9. DOI:10.3892/mmr.2015.4535; Wang W., Yang Z.L., Liu J.Q. et al. Overexpression of MTA1 and loss of KAI-1 and KiSS-1 expressions are associated with invasion, metastasis, and poor-prognosis of gallbladder adenocarcinoma. Tumori 2014;100(6):667–74. DOI:10.1700/1778.19276; Teng Y., Mei Y., Hawthorn L., Cowell J.K. WASF3 regulates miR-200 inactivation by ZEB1 through suppression of KISS1 leading to increased invasiveness in breast cancer cells. Oncogene 2014;33(2):203–11. DOI:10.1038/onc.2012.565; Zhu N., Zhao M., Song Y. et al. The KiSS-1/GPR54 system: Essential roles in physiological homeostasis and cancer biology. Genes Dis 2022;9(1):28–40. DOI:10.1016/j.gendis.2020.07.008; Ohtaki T., Shintani Y., Honda S. et al. Metastasis suppressor gene KiSS-1 encodes peptide ligand of a G-protein-coupled receptor. Nature 2001;411(6837):613–7. DOI:10.1038/35079135; Kuohung W., Kaiser U.B. GPR54 and KiSS-1: role in the regulation of puberty and reproduction. Rev Endocr Metab Disord 2006;7(4):257–63. DOI:10.1007/s11154-006-9020-2; Francis V.A., Abera A.B., Matjila M. et al. Kisspeptin regulation of genes involved in cell invasion and angiogenesis in first trimester human trophoblast cells. PLoS One 2014;9(6):e99680. DOI:10.1371/journal.pone.0099680; Ciaramella V., Della Corte C.M., Ciardiello F., Morgillo F. Kisspeptin and cancer: molecular interaction, biological functions, and future perspectives. Front Endocrinol (Lausanne) 2018;9:115. DOI:10.3389/fendo.2018.00115; Loosen S.H., Luedde M., Lurje G. et al. Serum levels of kisspeptin are elevated in patients with pancreatic cancer. Dis Markers 2019;2019:5603474. DOI:10.1155/2019/5603474; Canbay E., Ergen A., Bugra D. et al. Kisspeptin-54 levels are increased in patients with colorectal cancer. World J Surg 2012;36(9):2218–24. DOI:10.1007/s00268-012-1636-7; Ergen A., Canbay E., Bugra D. et al. Plasma Kisspeptin-54 levels in gastric cancer patients. Int J Surg 2012;10(9):551–4. DOI:10.1016/j.ijsu.2012.08.014; Gatti L., Rolli L., Corno C. et al. Increased serum levels of KiSS1- derived peptides in non-small cell lung cancer patient liquid biopsies and biological relevance. Transl Lung Cancer Res 2022;11(7):1315–26. DOI:10.21037/tlcr-22-52; Harihar S., Ray S., Narayanan S. et al. Role of the tumor microenvironment in regulating the anti-metastatic effect of KISS1. Clin Exp Metastasis 2020;37(2):209–23. DOI: 0.1007/s10585-020-10030-6; Zheng S., Chang Y., Hodges K.B. et al. Expression of KISS1 and MMP-9 in non-small cell lung cancer and their relations to metastasis and survival. Anticancer Res 2010;30(3):713–8.; https://oncourology.abvpress.ru/oncur/article/view/1724
-
2Academic Journal
المؤلفون: N. E. Kushlinskii, O. V. Kovaleva, P. L. Prishchep, N. N. Zybina, V. Jurisic, A. A. Alferov, Yu. B. Kuzmin, I. O. Goryacheva, I. N. Kuznetsov, I. V. Bulytcheva, S. R. Varfolomeeva, E. A. Sushentsov, E. S. Gershtein, D. V. Rogozhin, O. O. Yanushevich, I. S. Stilidi, Н. Е. Кушлинский, О. В. Ковалева, П. Л. Прищеп, Н. Н. Зыбина, В. Юришич, А. А. Алферов, Ю. Б. Кузьмин, И. О. Горячева, И. Н. Кузнецов, И. В. Булычева, С. Р. Варфоломеева, Е. А. Сушенцов, Е. С. Герштейн, Д. В. Рогожин, О. О. Янушевич, И. С. Стилиди
المصدر: Bulletin of Siberian Medicine; Том 22, № 2 (2023); 68-77 ; Бюллетень сибирской медицины; Том 22, № 2 (2023); 68-77 ; 1819-3684 ; 1682-0363 ; 10.20538/1682-0363-2023-22-2
مصطلحات موضوعية: прогноз, galectin-3, blood serum, prognosis, галектин-3, сыворотка крови
وصف الملف: application/pdf
Relation: https://bulletin.ssmu.ru/jour/article/view/5222/3395; https://bulletin.ssmu.ru/jour/article/view/5222/3418; Dumic J., Dabelic S., Flögel M. Galectin-3: an open-ended story. Biochim. Biophys. Acta. 2006;1760(4):616–635. DOI:10.1016/j.bbagen.2005.12.020.; Liu F.T., Hsu D.K. The role of galectin-3 in promotion of the inflammatory response. Drug News Perspect. 2007;20(7):455– 460. DOI:10.1358/dnp.2007.20.7.1149628.; Clementy N., Garcia B., André C., Bisson A., Benhenda N., Pierre B. et al. Galectin-3 level predicts response to ablation and outcomes in patients with persistent atrial fibrillation and systolic heart failure. PLoS One. 2018;13(8):e0201517. DOI:10.1371/journal.pone.0201517.; Asleh R., Enriquez-Sarano M., Jaffe A.S., Manemann S.M., Weston S.A., Jiang R. et al Galectin-3 Levels and Outcomes After Myocardial Infarction: A Population-Based Study. J. Am. Coll. Cardiol. 2019;73(18):2286–2295. DOI:10.1016/j.jacc.2019.02.046.; Chen S.C., Kuo P.L. The role of galectin-3 in the kidneys. Int. J. Mol. Sci. 2016;17(4):565. DOI:10.3390/ijms17040565.; Li Y., Li T., Zhou Z., Xiao Y. Emerging roles of galectin-3 in diabetes and diabetes complications: A snapshot. Rev. Endocr. Metab. Disord. 2022;23(3):569–577. DOI:10.1007/s11154-021-09704-7.; Wang W.H., Lin C.Y., Chang M.R., Urbina A.N., Assavalapsakul W., Thitithanyanont A. et al. The role of galectins in virus infection - A systemic literature review. J. Microbiol. Immunol. Infect. 2020;53(6):925–935. DOI:10.1016/j.jmii.2019. 09.005.; De Oliveira F.L., Gatto M., Bassi N., Luisetto R., Ghirardello A., Punzi L. et al. Galectin-3 in autoimmunity and autoimmune diseases. Exp. Biol. Med. (Maywood). 2015;240(8):1019– 1028. DOI:10.1177/1535370215593826.; Ashraf G.M., Baeesa S.S. Investigation of gal-3 expression pattern in serum and cerebrospinal fluid of patients suffering from neurodegenerative disorders. Front. Neurosci. 2018;12:430. DOI:10.3389/fnins.2018.00430.; Song L., Tang J.W., Owusu L., Sun M.Z., Wu J., Zhang J. Galectin-3 in cancer. Clin. Chim. Acta. 2014;431:185–191. DOI:10.1016/j.cca.2014.01.019.; Xie L., Ni W.K., Chen X.D., Xiao M.B., Chen B.Y., He S. et al. The expressions and clinical significances of tissue and serum galectin-3 in pancreatic carcinoma. J. Cancer Res. Clin. Oncol. 2012;138(6):1035–1043. DOI:10.1007/s00432-012-1178-2.; Matsuda Y., Yamagiwa Y., Fukushima K., Ueno Y., Shimosegawa T. Expression of galectin-3 involved in prognosis of patients with hepatocellular carcinoma. Hepatol. Res. 2008;38(11):1098–1111. DOI:10.1111/j.1872-034X.2008.00387.x.; Kim S.J., Lee S.J., Sung H.J., Choi I.K., Choi C.W., Kim B.S. et al. Increased serum 90K and Galectin-3 expression are associated with advanced stage and a worse prognosis in diffuse large B-cell lymphomas. Acta Haematol. 2008;120(4):211– 216. DOI:10.1159/000193223.; Acikalin M.F., Etiz D., Gurbuz M.K., Ozudogru E., Canaz F., Colak E. Prognostic significance of galectin-3 and cyclin D1 expression in undifferentiated nasopharyngeal carcinoma. Med. Oncol. 2012;29(2):742–749. DOI:10.1007/s12032-011- 9971-3.; Endo K., Kohnoe S., Tsujita E., Watanabe A., Nakashima H., Baba H. et al. Galectin-3 expression is a potent prognostic marker in colorectal cancer. Anticancer Res. 2005;25(4):3117– 3121.; Zhang X.M., Yao G.Y., Zhang B.Y., Wang L.L., Zhao M. [Study on the expression and significance of Galectin-3 and CDC25B mRNA in human gastric carcinoma]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2009;26(3):288–292. (In Chinese). DOI:10.3760/cma.j.issn.1003-9406.2009.03.011.; Yang Z.M., Wu X.T., He T., Da M.X., Luo T., Qian K. [Expression of galectin-3 mRNA in gastric cancer with peritoneal metastasis]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2006;37(1):105–108. (In Chinese).; O’Driscoll L., Linehan R., Liang Y.H., Joyce H., Oglesby I., Clynes M. Galectin-3 expression alters adhesion, motility and invasion in a lung cell line (DLKP), in vitro. Anticancer Res. 2002;22(6A):3117–3125.; Castronovo V., Van Den Brûle F.A., Jackers P., Clausse N., Liu F.T., Gillet C. et al. Decreased expression of galectin-3 is associated with progression of human breast cancer. J. Pathol. 1996;179(1):43–48. DOI:10.1002/(SICI)1096-9896(199605)179:13.0.CO;2-N.; Knapp J.S., Lokeshwar S.D., Vogel U., Hennenlotter J., Schwentner C., Kramer M.W. et al. Galectin-3 expression in prostate cancer and benign prostate tissues: correlation with biochemical recurrence. World J. Urol. 2013;31(2):351–358. DOI:10.1007/s00345-012-0925-y.; Wang Y., Nangia-Makker P., Tait L., Balan V., Hogan V., Pienta K.J. et al. Regulation of prostate cancer progression by galectin-3. Am. J. Pathol. 2009;174(4):1515–1523. DOI:10.2353/ajpath.2009.080816.; Zhou X., Jing J., Peng J., Mao W., Zheng Y., Wang D. et al. Expression and clinical significance of galectin-3 in osteosarcoma. Gene. 2014;546(2):403–407. DOI:10.1016/j.gene.2014.04.066.; Park G.B., Kim D.J., Kim Y.S., Lee H.K., Kim C.W., Hur D.Y. Silencing of galectin-3 represses osteosarcoma cell migration and invasion through inhibition of FAK/Src/Lyn activation and β-catenin expression and increases susceptibility to chemotherapeutic agents. Int. J. Oncol. 2015;46(1):185– 194. DOI:10.3892/ijo.2014.2721.; Dong R., Zhang M., Hu Q., Zheng S., Soh A., Zheng Y. et al. Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy. Int. J. Mol. Med. 2018;41(2):599–614. DOI:10.3892/ijmm.2017.3311.; Crompton B.D., Stewart C., Taylor-Weiner A., Alexe G., Kurek K.C., Calicchio M.L. et al. The genomic landscape of pediatric Ewing sarcoma. Cancer Discov. 2014;4(11):1326– 1341. DOI:10.1158/2159-8290.CD-13-1037.; Huang Z., Ai Z., Li N., Xi H., Gao X., Wang F. et al. Over expression of galectin-3 associates with short-term poor prognosis in stage II colon cancer. Cancer Biomark. 2016;17(4):445– 455. DOI:10.3233/CBM-160661.; Okada K., Shimura T., Suehiro T., Mochiki E., Kuwano H. Reduced galectin-3 expression is an indicator of unfavorable prognosis in gastric cancer. Anticancer Res. 2006;26(2B):1369–1376.; https://bulletin.ssmu.ru/jour/article/view/5222